Publicaciones (44) Publicaciones de Sergio Vázquez Estévez

2024

  1. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

  2. Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study

    Clinical and Translational Oncology

  3. Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer

    Frontiers in Oncology, Vol. 14

  4. Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer

    Cancers, Vol. 16, Núm. 14

  5. Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer

    Clinical and Translational Oncology

2023

  1. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

    Prostate, Vol. 83, Núm. 4, pp. 376-384

  2. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

    The Lancet, Vol. 401, Núm. 10379, pp. 821-832

  3. Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial

    Targeted Oncology, Vol. 18, Núm. 5, pp. 639-641

2022

  1. Circulating Proteins Associated with Response and Resistance to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

    Cancers, Vol. 14, Núm. 4

  2. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)

    Lung Cancer, Vol. 173, pp. 83-93

  3. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer

    Oral Oncology, Vol. 134

2021

  1. Blood-based protein biomarkers in bladder urothelial tumors

    Journal of Proteomics, Vol. 247

  2. Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial

    Molecular Oncology, Vol. 15, Núm. 1, pp. 43-56

  3. Detection of circulating serum protein biomarkers of non-muscle invasive bladder cancer after protein corona-silver nanoparticles analysis by swath-ms

    Nanomaterials, Vol. 11, Núm. 9

  4. Proteomics as a complementary technique to characterize bladder cancer

    Cancers, Vol. 13, Núm. 21

2020

  1. A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus

    Clinical and Translational Oncology, Vol. 22, Núm. 9, pp. 1565-1579

  2. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)

    Lung Cancer, Vol. 150, pp. 62-69

  3. Identification of a profile of neutrophil-derived granule proteins in the surface of gold nanoparticles after their interaction with human breast cancer sera

    Nanomaterials, Vol. 10, Núm. 6, pp. 1-18

  4. Potential clinical applications of the personalized, disease-specific protein corona on nanoparticles

    Clinica Chimica Acta, Vol. 501, pp. 102-111

  5. Proteomic investigation on bio-corona of Au, Ag and Fe nanoparticles for the discovery of triple negative breast cancer serum protein biomarkers

    Journal of Proteomics, Vol. 212